Investment in Prescription to Over the Counter Switch Incubators Aims to Support Patient Self Care
Complete the form below to unlock access to ALL audio articles.
BioCity has announced investment in Maxwellia’s prescription (Rx) to
Over the Counter (OTC) switch incubator. The creation of new OTC products
potentially enables quicker therapeutic outcomes for many, who may not
previously have sought treatment. For the NHS, the shift towards self-care also
supports the wider public health issues by freeing-up GP's time. Maxwellia’s
approach converts prescription drugs into versions that can be purchased
without prescription from pharmacies and supermarkets; a process known as
‘switching’.
BioCity investment analyst, Dr. Imelda Juniarsih said "By providing
consumers with quicker, wider and more convenient access to medicines and
reducing the burden felt by the NHS, Maxwellia could support and accelerate the
move towards self-care and provide early intervention opportunities for some
long-term conditions in the UK.”
